Immuneering Corporation (IMRX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 44.76M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 6.36M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -63.47M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $44.76M | (m) | $6.36M | $-63.47M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $41.22M | (m) | $6.26M | $-59.23M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $42.05M | (m) | $6.31M | $-59.38M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $47.65M | (m) | $6.40M | $-64.18M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $48.04M | (m) | $6.58M | $-64.07M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $48.23M | (m) | $6.72M | $-64.23M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $47.96M | (m) | $6.50M | $-64.07M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $45.02M | (m) | $6.42M | $-61.82M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $43.81M | (m) | $6.26M | $-60.47M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $42.62M | (m) | $5.93M | $-59.06M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $41.62M | $0.00 | $5.73M | $-58.41M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $39.59M | $455.00 | $5.13M | $-56.10M | (m) | 8700130.99% | 1128507.69% | (m) | (m) |
| 2023-06-30 | $38.90M | $38.84K | $4.72M | $-55.36M | (m) | 100165.41% | 12158.52% | (m) | (m) |
| 2023-03-31 | $37.42M | $133.25K | $4.44M | $-53.50M | (m) | 28081.33% | 3332.21% | (m) | (m) |
| 2022-12-31 | $36.27M | $316.95K | $4.06M | $-51.74M | (m) | 11442.46% | 1282.35% | (m) | (m) |
| 2022-09-30 | $34.35M | $506.09K | $3.65M | $-48.88M | (m) | 6786.54% | 720.99% | (m) | (m) |
| 2022-06-30 | $31.19M | $949.84K | $3.22M | $-44.23M | (m) | 3283.66% | 338.95% | (m) | (m) |
| 2022-03-31 | $30.21M | $1.52M | $2.52M | $-40.58M | (m) | 1993.36% | 166.16% | (m) | (m) |
| 2021-12-31 | $26.54M | $2.08M | $1.80M | $-33.89M | (m) | 1276.03% | 86.67% | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $15.00M | $2.31M | $1.09M | $-17.08M | (m) | 649.08% | 47.02% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |